vs
Side-by-side financial comparison of La Rosa Holdings Corp. (LRHC) and Intellia Therapeutics, Inc. (NTLA). Click either name above to swap in a different company.
Intellia Therapeutics, Inc. is the larger business by last-quarter revenue ($23.0M vs $20.2M, roughly 1.1× La Rosa Holdings Corp.). La Rosa Holdings Corp. runs the higher net margin — -27.4% vs -416.2%, a 388.8% gap on every dollar of revenue. On growth, Intellia Therapeutics, Inc. posted the faster year-over-year revenue change (78.8% vs 3.2%). Over the past eight quarters, La Rosa Holdings Corp.'s revenue compounded faster (72.5% CAGR vs -10.8%).
V. La Rosa and Sons Macaroni Company was founded in 1914 by Vincenzo La Rosa, a Sicilian immigrant. The company eventually became one of the largest regional brands in the United States producing over 40 varieties of pasta.
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineere...
LRHC vs NTLA — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $20.2M | $23.0M |
| Net Profit | $-5.5M | $-95.8M |
| Gross Margin | 8.4% | — |
| Operating Margin | -24.7% | -428.9% |
| Net Margin | -27.4% | -416.2% |
| Revenue YoY | 3.2% | 78.8% |
| Net Profit YoY | -125.7% | 25.7% |
| EPS (diluted) | $-5.44 | $-0.81 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $23.0M | ||
| Q3 25 | $20.2M | $13.8M | ||
| Q2 25 | $23.2M | $14.2M | ||
| Q1 25 | $17.5M | $16.6M | ||
| Q4 24 | $17.7M | $12.9M | ||
| Q3 24 | $19.6M | $9.1M | ||
| Q2 24 | $19.1M | $7.0M | ||
| Q1 24 | $13.1M | $28.9M |
| Q4 25 | — | $-95.8M | ||
| Q3 25 | $-5.5M | $-101.3M | ||
| Q2 25 | $78.4M | $-101.3M | ||
| Q1 25 | $-95.7M | $-114.3M | ||
| Q4 24 | $-5.1M | $-128.9M | ||
| Q3 24 | $-2.5M | $-135.7M | ||
| Q2 24 | $-2.3M | $-147.0M | ||
| Q1 24 | $-4.6M | $-107.4M |
| Q4 25 | — | — | ||
| Q3 25 | 8.4% | — | ||
| Q2 25 | 8.0% | — | ||
| Q1 25 | 8.8% | — | ||
| Q4 24 | 8.9% | — | ||
| Q3 24 | 8.3% | — | ||
| Q2 24 | 8.3% | — | ||
| Q1 24 | 8.9% | — |
| Q4 25 | — | -428.9% | ||
| Q3 25 | -24.7% | -808.9% | ||
| Q2 25 | -10.6% | -772.2% | ||
| Q1 25 | -26.7% | -726.6% | ||
| Q4 24 | -17.1% | -1059.9% | ||
| Q3 24 | -8.9% | -1589.0% | ||
| Q2 24 | -9.7% | -1998.6% | ||
| Q1 24 | -35.0% | -394.0% |
| Q4 25 | — | -416.2% | ||
| Q3 25 | -27.4% | -735.2% | ||
| Q2 25 | 337.8% | -710.8% | ||
| Q1 25 | -546.5% | -687.6% | ||
| Q4 24 | -28.7% | -1001.2% | ||
| Q3 24 | -12.5% | -1489.5% | ||
| Q2 24 | -12.2% | -2112.6% | ||
| Q1 24 | -35.1% | -371.3% |
| Q4 25 | — | $-0.81 | ||
| Q3 25 | $-5.44 | $-0.92 | ||
| Q2 25 | $15.25 | $-0.98 | ||
| Q1 25 | $-5.86 | $-1.10 | ||
| Q4 24 | $28.54 | $-1.27 | ||
| Q3 24 | $-16.49 | $-1.34 | ||
| Q2 24 | $-12.49 | $-1.52 | ||
| Q1 24 | $-0.35 | $-1.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $4.0M | $449.9M |
| Total DebtLower is stronger | $642.8K | — |
| Stockholders' EquityBook value | $1.6M | $671.4M |
| Total Assets | $21.7M | $842.1M |
| Debt / EquityLower = less leverage | 0.41× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $449.9M | ||
| Q3 25 | $4.0M | $511.0M | ||
| Q2 25 | $5.1M | $459.7M | ||
| Q1 25 | $2.9M | $503.7M | ||
| Q4 24 | $1.4M | $601.5M | ||
| Q3 24 | $1.8M | $658.1M | ||
| Q2 24 | $1.6M | $691.1M | ||
| Q1 24 | $1.1M | $791.3M |
| Q4 25 | — | — | ||
| Q3 25 | $642.8K | — | ||
| Q2 25 | $644.3K | — | ||
| Q1 25 | $645.9K | — | ||
| Q4 24 | $647.6K | — | ||
| Q3 24 | $649.2K | — | ||
| Q2 24 | $650.8K | — | ||
| Q1 24 | $652.4K | — |
| Q4 25 | — | $671.4M | ||
| Q3 25 | $1.6M | $748.4M | ||
| Q2 25 | $3.4M | $715.3M | ||
| Q1 25 | $-87.5M | $779.9M | ||
| Q4 24 | $2.6M | $872.0M | ||
| Q3 24 | $5.0M | $962.6M | ||
| Q2 24 | $4.7M | $971.1M | ||
| Q1 24 | $5.6M | $1.0B |
| Q4 25 | — | $842.1M | ||
| Q3 25 | $21.7M | $925.3M | ||
| Q2 25 | $22.9M | $898.9M | ||
| Q1 25 | $21.0M | $986.2M | ||
| Q4 24 | $19.4M | $1.2B | ||
| Q3 24 | $19.7M | $1.2B | ||
| Q2 24 | $18.7M | $1.2B | ||
| Q1 24 | $16.3M | $1.3B |
| Q4 25 | — | — | ||
| Q3 25 | 0.41× | — | ||
| Q2 25 | 0.19× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.25× | — | ||
| Q3 24 | 0.13× | — | ||
| Q2 24 | 0.14× | — | ||
| Q1 24 | 0.12× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.3M | $-69.3M |
| Free Cash FlowOCF − Capex | — | $-69.4M |
| FCF MarginFCF / Revenue | — | -301.6% |
| Capex IntensityCapex / Revenue | — | 0.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-395.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-69.3M | ||
| Q3 25 | $-1.3M | $-76.9M | ||
| Q2 25 | $-1.4M | $-99.6M | ||
| Q1 25 | $-3.5M | $-148.9M | ||
| Q4 24 | $-1.1M | $-85.2M | ||
| Q3 24 | $-591.6K | $-84.8M | ||
| Q2 24 | $-803.1K | $-58.2M | ||
| Q1 24 | $-538.3K | $-120.7M |
| Q4 25 | — | $-69.4M | ||
| Q3 25 | — | $-76.9M | ||
| Q2 25 | — | $-99.9M | ||
| Q1 25 | — | $-149.7M | ||
| Q4 24 | — | $-86.2M | ||
| Q3 24 | — | $-86.1M | ||
| Q2 24 | — | $-59.2M | ||
| Q1 24 | — | $-123.2M |
| Q4 25 | — | -301.6% | ||
| Q3 25 | — | -558.2% | ||
| Q2 25 | — | -701.0% | ||
| Q1 25 | — | -900.1% | ||
| Q4 24 | — | -669.4% | ||
| Q3 24 | — | -945.2% | ||
| Q2 24 | — | -850.9% | ||
| Q1 24 | — | -425.7% |
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 0.2% | ||
| Q2 25 | — | 1.7% | ||
| Q1 25 | — | 4.4% | ||
| Q4 24 | — | 7.6% | ||
| Q3 24 | — | 14.0% | ||
| Q2 24 | — | 14.5% | ||
| Q1 24 | — | 8.7% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -0.02× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LRHC
| Real Estate Residential Brokerage Services | $16.8M | 83% |
| Transferred Over Time | $3.5M | 17% |
NTLA
| Avencell Therapeutics Inc | $21.0M | 91% |
| Other | $1.0M | 4% |
| Avencell | $1.0M | 4% |
